Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Clot Protection Benefits Evaluated for New Blood Gas Testing System

By LabMedica International staff writers
Posted on 12 Sep 2012
The clot protection capabilities of a new blood gas testing system have been highlighted in an evaluation undertaken at a hospital intensive care unit.

Blood sample clotting is a main concern in point-of-care (POC) testing systems (particularly in neonates for whom blood gases are the most common test performed) and can lead to delayed results and treatment, inconvenient analyzer downtime, and increased work and stress for hospital staff. More...
At the intensive care unit of Stepping Hill Hospital of Stockport NHS Foundation Trust (Stockport, UK), 175 patient samples, including about 30 considered “high risk” for clotting, were analyzed in an evaluation of the new “Roche cobas b 123 POC” system from Roche Diagnostics (Basel, Switzerland). The tests were performed by nursing staff; quality control testing was performed automatically by AutoQC twice daily.

“We never had a problem with clots throughout the entire evaluation, despite using a wide variety of samples of varying condition and age,” said Samantha Ekin, Point of Care Coordinator (PCC) at the Trust. “This will be vital in a delivery suite setting where the quality of samples can be lower. The small size of the analyzer is great as it can be housed more easily, and it is portable.”

The cobas b 123 is specifically designed to eliminate risk of clot blockages. A new clot clearance feature prevents movement of clots from the syringe or capillary into the analyzer. This is achieved using a dual-action preanalytical barrier, with bottlenecks in the sample port needle and the cooximetry measuring chamber, so that clots are simply rinsed away with the sample by the automated default washing routine. Built-in optical sensors detect whether the lack of fluid path flow is due to a clot, in which case a series of automated expulsion steps remove the clot before continuing analysis uninterrupted.

To date, in both internal and external ongoing evaluations, no downtime owing to clots has been reported for the Roche cobas b 123 POC. The system is very easy to use and requires very little maintenance. “The whole process of analyzing a patient sample was very easy for the operator,” PPC Ekin continues; “This is very important because if the nurses like the analyzer they will have confidence to use it and confidence in the results. The low maintenance is also extremely important, especially for ‘out of hours’ work, as it enables the operators to perform any maintenance that might be required.” She adds that since training is very simple and requires less time, the procedure would be more accessible to additional staff.

Related Links:
Roche Diagnostics
Stockport NHS Foundation Trust


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Industry

view channel
Image: NeoGenomics selected Indica Labs’ HALO AP platform to eable its digital pathology operations through a scalable, cloud-based framework (Photo courtesy of Indica Labs)

Expanded Partnership Scales AI-Powered Digital Pathology for Oncology

Oncology diagnostics rely on pathology and biomarker information to guide personalized treatment. As computational pathology and artificial intelligence (AI) expand insights from tissue analysis, laboratories... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.